Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
72%
Acute Myeloid Leukemia
48%
Hematological Malignancies
42%
Confidence Interval
29%
High Risk
28%
Hematopoietic Cell Transplant
27%
Chemotherapy
23%
Frailty
22%
Hazard Ratio
22%
Overall Survival
17%
Clinical Outcomes
16%
Hematopoietic Cell Transplantation
16%
Reduced-intensity Conditioning
16%
Relapse Risk
15%
5-year Survival
14%
Cytarabine
14%
Leukemia Patients
14%
Epidermal Growth Factor
13%
Older Patients
13%
Treatment-related Mortality
12%
Donor Lymphocyte Infusion
12%
Lymphoma
12%
Cell Dose
12%
CD34+ Cells
12%
High Incidence
12%
Host Interaction
11%
Combination Therapy
11%
Peripheral Blood
11%
Thromboembolism
11%
Recombinant Human
11%
Human Chorionic Gonadotropin
11%
ABO Blood Group
11%
Hematopoietic Engraftment
11%
Interleukin-15 (IL-15)
11%
Donor-recipient Matching
11%
Foscarnet
11%
Intravascular Large B-cell Lymphoma (IVLBCL)
11%
Hematopoietic Stem Cell Transplantation
11%
Clinical Trials Network
11%
Clofarabine
11%
Patient Prognosis
11%
Haploidentical
11%
Human Herpesvirus 6 (HHV-6)
11%
Angiogenic Factors
11%
Disease Risk Prediction
11%
Umbilical Cord Blood Transplantation
11%
Life-threatening
11%
Favorable Risk
11%
Immunohistochemistry
11%
Medicine and Dentistry
Hematopoietic Cell
72%
Cell Transplantation
61%
Acute Myeloid Leukemia
48%
Graft Versus Host Reaction
26%
Cytarabine
22%
Frailty
22%
Hematologic Malignancy
18%
Hazard Ratio
18%
Neoplasm
16%
Overall Survival
14%
Prevalence
13%
Acute Graft Versus Host Disease
13%
Combination Therapy
11%
Blood Group ABO System
11%
Large-Cell Lymphoma
11%
B-Cell Chronic Lymphocytic Leukemia
11%
Von Willebrand Factor
11%
Chorionic Gonadotropin
11%
Diffuse Large B-Cell Lymphoma
11%
Stem Cell Transplant
11%
Clofarabine
11%
Immunohistochemistry
11%
Infection
11%
Thromboembolism
11%
Cell Therapy
11%
Hematopoietic Stem Cell Transplantation
11%
Epidermal Growth Factor
11%
Natural Killer Cell
11%
Keratinocyte Growth Factor
11%
Palifermin
11%
Interleukin 15
11%
Bone Marrow Biopsy
11%
Mycosis fungoides
11%
Quality of Life
11%
Physical Performance
11%
Breast Cancer
11%
Diseases
11%
Protein P53
10%
Urinary System
9%
Chronic Graft Versus Host Disease
8%
Positron Emission Tomography
6%
Drug Megadose
6%
Immunomodulation
5%
Immunotherapy
5%
Multivariate Analysis
5%
Immunology and Microbiology
Hematopoietic Cell
70%
Cell Transplantation
69%
Acute Graft Versus Host Disease
50%
Graft-Versus-Host Disease
39%
Overall Survival
26%
Myeloid
22%
Chronic Graft Versus Host Disease
18%
Engraftment
17%
Umbilical Cord Blood
17%
Epidermal Growth Factor
13%
CD34
12%
Natural Killer Cell
11%
B Cell
11%
Conditioning
11%
Human Herpesvirus 6
11%
ABO Blood Group System
11%
Cord Blood Stem Cell Transplantation
11%
Blood Plasma
11%
Interleukin 15
11%
Angiogenic Factor
11%
Hematopoietic Stem Cell Transplantation
11%
Prevalence
11%
Lymphocyte
11%
Allogeneic Hematopoietic Stem Cell Transplantation
11%
Immunomodulation
6%
Positron Emission Tomography
6%